Journal article
Analysis of the effect of primaquine dose on efficacy, safety, and tolerability in patients with Plasmodium vivax malaria in Ethiopia: a systematic review and individual patient data meta-analysis.
Tamiru Shibiru Degaga, Kamala Thriemer, Megha Rajasekhar, Tesfay Abreha, Ashenafi Assefa, Nicholas M Douglas, Endalamaw Gadisa, Asrat Hailu, Jimee Hwang, Gavin CKW Koh, Marcus VG Lacerda, Alejandro Llanos-Cuentas, Daniel Abebe Mekonnen, Julie A Simpson, Fitsum G Tadesse, Walter RJ Taylor, Lorenz von Seidlein, Adugna Woyessa, Asnakew K Yeshiwondim, Daniel Yilma Show all
Malar J | Published : 2026
Open access
Abstract
BACKGROUND: The 8-aminoquinoline antimalarials are used to prevent P. vivax relapses. Recent evidence suggests high total dose primaquine (7 mg/kg) provides optimal efficacy, however, many countries, including Ethiopia, use low total dose primaquine (3.5 mg/kg). To understand the risks and benefits of different primaquine dosing regimens for P. vivax malaria in Ethiopia, we undertook a systematic review and individual patient data meta-analysis. METHODS: We searched for antimalarial efficacy studies in patients with uncomplicated P. vivax mono-infections conducted in Ethiopia, published between January 1, 2000, and March 8, 2024. Studies were included if they had at least 28 days of follow-u..
View full abstract